Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection
Related Experiment Video
Updated: May 9, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Shane Pearce1, Zoe Steinberg, Scott Eggener
1University of Chicago, Section of Urology, 5841 S. Maryland Avenue, MC6038, Chicago, IL, 60637, USA, shane.pearce@uchospitals.edu.
Abstract:
Retroperitoneal lymph node dissection (RPLND) is a critical aspect of staging and treatment of nonseminomatous germ cell tumors (NSGCTs) of the testis. RPLND achieves cure in a majority of patients with low-volume metastatic disease and minimizes the need for chemotherapy. Initial surgical approaches to RPLND, involving wide limits to dissection, were associated with high rates of retrograde ejaculation and significant overall morbidity. Evolving modified RPLND templates helped reduce rates of retrograde ejaculation but may be associated with a 3 %-23 % risk of unresected metastasis. Modified templates have become a standard of care in primary RPLND with low-volume metastatic disease. Only highly select patients at specialized centers should undergo modified template RPLND in the postchemotherapy setting, because risks of unresected disease are higher than in the primary setting. Bilateral RPLND optimizes cancer control and can preserve antegrade ejaculation if nerve sparing is performed. We also briefly discuss minimally invasive approaches to RPLND.
Insights
Retroperitoneal lymph node dissection (RPLND) is key for testicular nonseminomatous germ cell tumors (NSGCTs). Modified templates balance cure rates and ejaculation preservation, but careful patient selection is crucial.
Area of Science:
- Urology
- Surgical Oncology
- Medical Oncology
Background:
- Retroperitoneal lymph node dissection (RPLND) is integral to managing testicular nonseminomatous germ cell tumors (NSGCTs).
- Historically, extensive RPLND led to high rates of retrograde ejaculation and morbidity.
- Evolving surgical templates aim to balance oncologic control with functional preservation.
Purpose of the Study:
- To review the role and evolution of RPLND in NSGCT management.
- To discuss the oncologic outcomes and functional sequelae of different RPLND approaches.
- To provide guidance on patient selection for primary and post-chemotherapy RPLND.
Main Methods:
- Review of surgical techniques and outcomes for RPLND in NSGCT.
- Analysis of modified RPLND templates and their impact on metastasis and ejaculation.
- Discussion of nerve-sparing bilateral RPLND and minimally invasive approaches.
Main Results:
- Modified RPLND templates reduce retrograde ejaculation but carry a 3-23% risk of unresected metastasis.
- Primary modified RPLND is standard for low-volume disease; post-chemotherapy use requires careful selection.
- Bilateral nerve-sparing RPLND can optimize cancer control and preserve antegrade ejaculation.
Conclusions:
- RPLND remains a cornerstone in NSGCT treatment, with evolving techniques improving functional outcomes.
- Patient selection and surgical approach must be tailored to disease volume and treatment setting (primary vs. post-chemotherapy).
- Minimally invasive techniques and nerve-sparing bilateral dissection warrant further consideration.